Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

-- Late-breaking oral presentations to highlight data from plazomicin Phase 3 EPIC and CARE clinical trials --

-- Newly-released in vitro data demonstrates activity of plazomicin against a large collection of colistin-resistant Enterobacteriaceae, including strains carrying the mobilized colistin resistance  (mcr-1) gene --

SOUTH SAN FRANCISCO, Calif., April 13, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced seven upcoming presentations on plazomicin at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID). The company and its collaborators will deliver two oral presentations and five poster presentations at the event, which will be held in Vienna, Austria from April 22 to 25, 2017. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Oral Presentations
Both oral presentations will take place on Saturday, April 22, 2017 during a late-breaker, Recent Clinical Trials session from 4:30pm to 6:30pm CET.

Title: Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract
infection (cUTI) and Acute Pyelonephritis (AP): Results of the EPIC Study
Authors: D.Cloutier (presenter), L.Miller, A.Komirenko, D.Cebrik, K.Krause, T.Keepers,
L.Connolly, F.Wagenlehner
   
Title: Plazomicin Associated with Improved Survival and Safety Compared to Colistin in
Serious Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Results of the
CARE Study
Authors: G.Daikos, L.Connolly (presenter), A.Jubb, B.O'Keeffe, A.Serio, A.Smith, J.Gall,
V.Riddle, K.Krause, J.McKinnell, E.Zakynthinos

Poster Presentations
All poster presentations will take place on Monday, April 24, 2017, from 12:30 – 1:30pm CET, unless noted otherwise (abstract #1600).

Title: In vitro Activity of Plazomicin Against Colistin-Resistant Enterobacteriaceae
Including Plasmid-Encoded MCR-1-Producing Isolates (Abstract #1156)
Authors: P. Nordmann, V.Denervaud, L.Connolly, K.Krause
Session: P059: Activity of newer and older antimicrobials against Gram-negative
organisms
   
Title: Activity of Plazomicin and Comparator Agents Tested Against Recent Clinical
Isolates Collected in the Asia-Pacific Region, Europe and Latin America (Abstract
#3596)
Authors: M. Castanheira, J.Streit, L.Deshpande, R.Mendes, R.Flamm
Session: P059: Activity of newer and older antimicrobials against Gram-negative
organisms
   
Title: Plazomicin Activity Against European Enterobacteriaceae Isolates Carrying
Aminoglycoside-Modifying Enzymes and 16S rRNA Methylases (Abstract #3611)
Authors: M. Castanheira, T.Doyle, L.Woosley, A.Serio, K.Krause, R.Flamm
Session: P059: Activity of newer and older antimicrobials against Gram-negative
organisms
   
Title: In vitro Activity of Plazomicin and Underlying Resistance Mechanisms in
Enterobacteriaceae Isolated from Blood Isolates from Hospitalized Patients in
Turkey (Abstract #2614)
Authors: D. Gür, A.Cakar, U.Hasdemir, B.Aksu, E.Caglan, I.Cavusoglu, T.Celik
Session: P059: Activity of newer and older antimicrobials against Gram-negative
organisms
   
Title: Nationwide Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae
Isolates from Greek Hospitals, in Regards to Plazomicin and Aminoglycoside
Resistance (Abstract #1600)
Authors: I. Galani, K.Nafplioti, P.Adamou, I.Karaiskos, H.Giamarellou, M.Souli
Session: P020: Carbapenemases – here, there and everywhere
  Saturday, April 22, 2017, 3:30pm - 4:30pm CET
   

The abstracts can be accessed through the ECCMID website. Following the meeting, the presentation slides and posters will be available on the Achaogen website.

About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with Federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen’s expectations regarding potential regulatory approval of plazomicin and Achaogen’s commercial objectives. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; the risks and uncertainties of commercialization and gaining market acceptance; and the risk when bacteria will evolve resistance to plazomicin. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward- looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Achaogen, Inc.
AKAO-G

CONTACT: Investor Contact: 
Hans Vitzthum
212.915.2568
hans@lifesciadvisors.com

Media Contact: 
Denise Powell
510.703.9491
denise@redhousecomms.com

Ads